secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001683168-24-003191
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports positive in vitro Hemopurifier data for removing extracellular vesicles from cancer plasma
--------------------------------------------------------------------------------

- In vitro binding study of Hemopurifier shows removal of extracellular vesicles (EVs) directly from cancer patient plasma.
- Data supports planned Phase 1 trial in solid tumor patients on anti-PD-1 therapies (Keytruda/Opdivo).
- Descriptive statistics from CRO NAMSA confirm EV removal; PD-L1+ EV subset inconclusive due to low counts.
- Next step: submit data to Ethics Committees in Australia and India to initiate Phase 1 oncology studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316824003191/0001683168-24-003191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316824003191/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer